TDOC stock price traded around $16.24 in the latest New York session, showing modest intraday volatility of roughly 2.1%. Analysts note Teladoc Health’s telemedicine segment holds resilience despite broader digital health compression, with FY2024 revenue guided in the $2.6–$2.7 billion range. “On tariffs, the Administration is indicating progress on potential deals with Japan, Korea, and India, which could serve as templates for other trading partners. Of most importance is China, where the Administration has signaled some willingness to find a common ground and possibly get a deal done soon (the increasing risk of a small business default cycle kicking off is gaining attention).” While identifying Livongo as the “SaaS backbone of Teladoc,” Citron suggested that the performance of the BetterHelp therapy service has weighed on the stock. Looking ahead, the firm posited that a resolution to the current government shutdown could act as a significant catalyst for the shares. The virtual healthcare industry is projected to grow at a CAGR of over 20% through 2028, which could provide medium-term support for Teladoc’s valuation metrics.
